{"id":81799,"date":"2026-06-27T08:50:53","date_gmt":"2026-06-27T03:20:53","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/"},"modified":"2026-06-27T12:01:17","modified_gmt":"2026-06-27T06:31:17","slug":"telo-genomics-announces-termination-of-investor-relations-agreement","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/","title":{"rendered":"Telo Genomics Announces Termination of Investor Relations Agreement"},"content":{"rendered":"

<\/p>\n

Vancouver, British Columbia–(Newsfile Corp. – June 26, 2026) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)<\/b> (the “Company<\/b>” or “Telo Genomics<\/b>“), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC (“Sheridan<\/b>“), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties that this was a transitory role for Sheridan and was not intended to be long term. The Company wishes Sheridan well with its future endeavours.<\/p>\n

About Telo Genomics <\/b><\/p>\n

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com<\/a>.<\/p>\n

\n

For further information, please contact:<\/b>
\nJohn Price
\nChief Financial Officer
\n408-550-5767
\ninfo@telodx.com<\/a><\/p>\n<\/div>\n

555 Richmond Street West
\nToronto, ON, Canada, M5V 3B1
\nwww.telodx.com<\/a><\/p>\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/p>\n

Cautionary Note Regarding Forward-Looking Statements <\/b><\/i><\/p>\n

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual outcome to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.<\/i><\/p>\n

\"Corporate<\/p>\n

To view the source version of this press release, please visit https:\/\/www.newsfilecorp.com\/release\/303174<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Vancouver, British Columbia–(Newsfile Corp. – June 26, 2026) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics“), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC (“Sheridan“), as announced on …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32016],"tags":[30625],"class_list":["post-81799","post","type-post","status-publish","format-standard","","category-press-releases","tag-telo-genomics-corp"],"yoast_head":"\nTelo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Vancouver, British Columbia–(Newsfile Corp. – June 26, 2026) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics“), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC (“Sheridan“), as announced on …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-27T03:20:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-27T06:31:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/303174\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/\",\"name\":\"Telo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2026-06-27T03:20:53+00:00\",\"dateModified\":\"2026-06-27T06:31:17+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telo Genomics Announces Termination of Investor Relations Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Telo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English","og_description":"Vancouver, British Columbia–(Newsfile Corp. – June 26, 2026) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics“), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC (“Sheridan“), as announced on …","og_url":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2026-06-27T03:20:53+00:00","article_modified_time":"2026-06-27T06:31:17+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/303174\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/","url":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/","name":"Telo Genomics Announces Termination of Investor Relations Agreement - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2026-06-27T03:20:53+00:00","dateModified":"2026-06-27T06:31:17+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/27\/telo-genomics-announces-termination-of-investor-relations-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Telo Genomics Announces Termination of Investor Relations Agreement"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/81799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=81799"}],"version-history":[{"count":1,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/81799\/revisions"}],"predecessor-version":[{"id":81817,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/81799\/revisions\/81817"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=81799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=81799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=81799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}